NeoGenomics, Inc. (NGNM.OB) Reports Revenue Of $18.2 Million And Adjusted EBITDA Of $1.7 Million For The First Quarter
4/23/2014 6:51:34 AM
FT. MYERS, Fla., April 23, 2014 /PRNewswire/ -- NeoGenomics, Inc. , /quotes/zigman/13104278/delayed/quotes/nls/neo NEO +9.28% a leading provider of cancer-focused genetic testing services today reported its results for the first quarter of 2014.
First Quarter 2014 Highlights:
•Test volume growth of 21%
Help employers find you! Check out all the jobs and post your resume.
comments powered by